#South Korea #Seoul #FDA Clearance #CGBIO #EASYMADE TI

CGBIO Receives FDA 510(k) Clearance for EASYMADE TI

CGBIO, a leading biotechnology company based in South Korea, has achieved a significant milestone by obtaining FDA 510(k) clearance for its innovative patient-specific titanium implant known as EASYMADE TI. This achievement not only marks a breakthrough for the company but also positions it as the first Korean firm to secure regulatory approval from the U.S. Food and Drug Administration specifically for a customized titanium implant. The clearance was officially announced on April 24, 2026, following a premarket submission that demonstrated the implant’s substantial equivalence to existing devices already on the market.

The EASYMADE TI implant is meticulously designed based on individual CT imaging data, making it an ideal solution for cranial and craniofacial reconstruction procedures. Fabricated from medical-grade titanium alloy, the implant is produced using advanced Laser Powder Bed Fusion (LPBF) technology, which is a state-of-the-art method in 3D printing metals. This approach enables the creation of implants tailored to the unique anatomical needs of each patient, which is crucial during surgical interventions.

One of the noteworthy aspects of the EASYMADE TI implant is the expedited delivery process. Once CT scans from U.S.-based clinicians are received, CGBIO's design center in Korea promptly completes the customized designs. The final product is then shipped to hospitals within just five days, and after sterilization, it is ready for immediate surgical use. This efficient turnaround time is a game-changer in the field, where the need for quick and effective surgical solutions is paramount.

The demand for advanced cranial and craniofacial reconstruction techniques is on the rise in the United States. Factors driving this demand include an increase in trauma cases, tumor resections, and decompressive craniectomies, alongside a growing interest in customized solutions that conform closely to individual patient anatomies. CGBIO anticipates a significant expansion in its patient-specific implant business in the U.S. market, thanks to this FDA clearance.

Hyunseung Yu, CEO of CGBIO, expressed pride in this achievement, stating, "The FDA 510(k) clearance of EASYMADE TI is a meaningful milestone that underscores CGBIO's global competitiveness in patient-specific reconstruction solutions." Yu also indicated that this success will lay a solid foundation for the company's ongoing efforts to expand and capture a larger share of the U.S. market while accelerating the regulatory approval processes for its other pipeline products.

With its innovative approach and commitment to meeting the needs of healthcare professionals and patients alike, CGBIO is poised to strengthen its position in the competitive landscape of patient-specific medical devices. This clearance represents not just a regulatory success but a commitment to innovation, quality, and patient care that will define the future of personalized medical solutions.

In conclusion, the FDA’s approval of the EASYMADE TI implant illustrates a significant advancement in the field of cranial and craniofacial reconstruction, pushing the boundaries of what is possible in patient-specific healthcare solutions. CGBIO is set to play a pivotal role moving forward in providing tailored surgical options that enhance recovery and outcomes for patients across the U.S.